IRRs from trials of sirolimus and paclitaxel eluting stents and RIRR comparing sirolimus with paclitaxel in patients without diabetes
| Study | IRR (95% confidence interval) | |||
|---|---|---|---|---|
| In-stent restenosis | In-segment restenosis | TLR | MACE | |
| *I2, test of heterogeneity. | ||||
| Sirolimus trials | ||||
| SIRIUS (2003)4 | 0.05 (0.02 to 0.14) | 0.20 (0.11 to 0.34) | 0.21 (0.11 to 0.40) | 0.39 (0.25 to 0.62) |
| E-SIRIUS (2003)1 | 0.09 (0.03 to 0.24) | 0.13 (0.05 to 0.30) | 0.20 (0.08 to 0.52) | 0.42 (0.20 to 0.85) |
| C-SIRIUS (2004)3 | 0.04 (0.002 to 0.68) | 0.03 (0.002 to 0.54) | 0.13 (0.02 to 1.00) | 0.13 (0.02 to 1.00) |
| RAVEL (2004)2 | 0.02 (0.001 to 0.37) | 0.02 (0.001 to 0.37) | 0.02 (0.001 to 0.41) | 0.20 (0.08 to 0.53) |
| SES-SMART (2002)8 | NA | 0.11 (0.04 to 0.28) | NA | NA |
| Combined IRR | 0.06 (0.03 to 0.12) | 0.15 (0.10 to 0.22) | 0.19 (0.11 to 0.31) | 0.35 (0.25 to 0.50) |
| Heterogeneity* | 0.0%, p = 0.77 | 8.8%, p = 0.36 | 0.0%, p = 0.52 | 0.0%, p = 0.44 |
| Paclitaxel trials | ||||
| TAXUS I (2003)5 | NA | NA | 0.16 (0.01 to 3.13) | 0.28 (0.03 to 2.53) |
| TAXUS II (2003)6, 32, 33 | NA | 0.08 (0.02 to 0.24) | 0.29 (0.14 to 0.61) | NA |
| TAXUS IV (2004)7, 29 | 0.25 (0.13 to 0.47) | 0.35 (0.20 to 0.59) | 0.30 (0.19 to 0.48) | NA |
| TAXUS VI (2004)31 | 0.30 (0.17 to 0.53) | 0.39 (0.24 to 0.64) | 0.49 (0.27 to 0.88) | 0.80 (0.49 to 1.29) |
| Combined IRR | 0.28 (0.18 to 0.42) | 0.32 (0.23 to 0.45) | 0.35 (0.25 to 0.48) | 0.76 (0.48 to 1.22) |
| Heterogeneity* | 0.0%, p = 0.67 | 69.2%, p = 0.04 | 0.0%, p = 0.53 | 0.0%, p = 0.37 |
| RIRR (sirolimus v paclitaxel) | 0.21 (0.10 to 0.48) p<0.001 | 0.47 (0.24 to 0.92) p = 0.027 | 0.54 (0.30 to 0.99) p = 0.045 | 0.46 (0.26 to 0.83) p = 0.010 |